Literature DB >> 35597838

Association of hypertriglyceridemic waist phenotype with non-alcoholic fatty liver disease: a cross-sectional study in a Chinese population.

Yan Xuan1, Ping Gao1, Ying Shen1, Sujie Wang1, Xi Gu1, Dou Tang1, Xun Wang1, FanFan Zhu1, Leiqun Lu2, Ling Chen3.   

Abstract

BACKGROUND: The aim of this study was to determine the association between hypertriglyceridemic waist (HTGW) phenotype and non-alcoholic fatty liver disease (NAFLD) in a middle- to older-aged Chinese population.
METHODS: In this cross-sectional study, a total of 9015 participants (age 40-79 years) were recruited and grouped into four phenotypes, as follows: NWNT: normal waist-normal triglyceride; NWET: normal waist-elevated triglycerides; EWNT: elevated waist-normal triglycerides; and hypertriglyceridemic waist (HTGW). Logistic regression analysis was carried out to assess the associations between HTGW phenotype and NAFLD. Receiver-operating characteristic (ROC) curves were drawn to evaluate the utility of waist circumference-triglyceride index (WTI) as a reference factor for screening for NAFLD.
RESULTS: HTGW phenotype had a higher prevalence of NAFLD (53.3%), diabetes (19.6%), and hypertension (79.8%) than the other three subgroups. After adjusting for age, sex, and BMI, HTGW phenotype was associated with NAFLD (odds ratio (OR) 6.12; 95% confidence interval (CI) 5.11-7.32). Further adjusted for potential confounders, the HTGW phenotype was still significantly associated with NAFLD (adjusted OR 5.18; 95% CI 4.30-6.23) regardless of gender. The subgroup analyses generally revealed similar associations across all subgroups. ROC curve analysis showed that when the maximum area under the curve was 0.748, the WTI was 90.1, and the corresponding sensitivity and specificity were 90.6 and 59.5%, respectively.
CONCLUSIONS: HTGW phenotype is strongly associated with NAFLD and can be used as a reference factor for NAFLD screening.
© 2022. Hellenic Endocrine Society.

Entities:  

Keywords:  Central obesity; Chinese adults; Hypertriglyceridemia waist phenotype; NAFLD

Mesh:

Substances:

Year:  2022        PMID: 35597838     DOI: 10.1007/s42000-022-00374-x

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   3.419


  31 in total

1.  Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease.

Authors:  Yuichiro Eguchi; Takahisa Eguchi; Toshihiko Mizuta; Yasushi Ide; Tsutomu Yasutake; Ryuichi Iwakiri; Akitaka Hisatomi; Iwata Ozaki; Kyousuke Yamamoto; Yoichiro Kitajima; Yasunori Kawaguchi; Shigetaka Kuroki; Naofumi Ono
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

2.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Authors:  Chris Estes; Quentin M Anstee; Maria Teresa Arias-Loste; Heike Bantel; Stefano Bellentani; Joan Caballeria; Massimo Colombo; Antonio Craxi; Javier Crespo; Christopher P Day; Yuichiro Eguchi; Andreas Geier; Loreta A Kondili; Daniela C Kroy; Jeffrey V Lazarus; Rohit Loomba; Michael P Manns; Giulio Marchesini; Atsushi Nakajima; Francesco Negro; Salvatore Petta; Vlad Ratziu; Manuel Romero-Gomez; Arun Sanyal; Jörn M Schattenberg; Frank Tacke; Junko Tanaka; Christian Trautwein; Lai Wei; Stefan Zeuzem; Homie Razavi
Journal:  J Hepatol       Date:  2018-06-08       Impact factor: 25.083

Review 3.  Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis.

Authors:  G Musso; M Cassader; C Olivetti; F Rosina; G Carbone; R Gambino
Journal:  Obes Rev       Date:  2013-02-06       Impact factor: 9.213

4.  Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes.

Authors:  Susan Sam; Steven Haffner; Michael H Davidson; Ralph B D'Agostino; Steven Feinstein; George Kondos; Alfonso Perez; Theodore Mazzone
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 19.112

Review 5.  Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal.

Authors:  Naim Alkhouri; Laura J Dixon; Ariel E Feldstein
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2009-08       Impact factor: 3.869

6.  Identification of Hepatic Steatosis in Premenopausal and Postmenopausal Women Based on Phenotypes Combining Triglyceride Levels and Anthropometric Indices: A Cross-Sectional Study.

Authors:  Peng Ju Liu; Hui Ping Lou; Yan Ning Zhu
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-23       Impact factor: 3.168

7.  New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease.

Authors:  Guangmin Zuo; Liping Xuan; Zhuojun Xin; Yu Xu; Jieli Lu; Yuhong Chen; Meng Dai; Di Zhang; Weiqing Wang; Mian Li; Yufang Bi; Guang Ning; Min Xu
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 5.958

Review 8.  Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Giovanni Musso; Roberto Gambino; James H Tabibian; Mattias Ekstedt; Stergios Kechagias; Masahide Hamaguchi; Rolf Hultcrantz; Hannes Hagström; Seung Kew Yoon; Phunchai Charatcharoenwitthaya; Jacob George; Francisco Barrera; Svanhildur Hafliðadóttir; Einar Stefan Björnsson; Matthew J Armstrong; Laurence J Hopkins; Xin Gao; Sven Francque; An Verrijken; Yusuf Yilmaz; Keith D Lindor; Michael Charlton; Robin Haring; Markus M Lerch; Rainer Rettig; Henry Völzke; Seungho Ryu; Guolin Li; Linda L Wong; Mariana Machado; Helena Cortez-Pinto; Kohichiroh Yasui; Maurizio Cassader
Journal:  PLoS Med       Date:  2014-07-22       Impact factor: 11.069

9.  [Waist circumference as a marker for screening nonalcoholic fatty liver disease in obese adolescents].

Authors:  Ana Paula Grotti Clemente; Bárbara Dal Molin Netto; Joana Pereira de Carvalho-Ferreira; Raquel Munhoz da Silveira Campos; Aline de Piano Ganen; Lian Tock; Marco Túlio de Mello; Ana Raimunda Dâmaso
Journal:  Rev Paul Pediatr       Date:  2015-12-31

Review 10.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease.

Authors:  Audrey Deprince; Joel T Haas; Bart Staels
Journal:  Mol Metab       Date:  2020-10-01       Impact factor: 8.568

View more
  1 in total

1.  Note by Hormones' new editor: metabolic syndrome plus obesity and COVID-19, the two concurrent pandemics and the field of endocrinology.

Authors:  Constantine A Stratakis
Journal:  Hormones (Athens)       Date:  2022-09       Impact factor: 3.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.